Latest Biotech News

Researchers presented new evidence for using circulating tumor DNA to tailor treatment in oligometastatic cancers at ESTRO 2026, highlighting a blood-based approach aimed at improving how therapy...

An international clinical trial led by University College London and the London School of Hygiene & Tropical Medicine reported strong performance from an AI tool used for radiotherapy planning in...

At ESTRO 2026, investigators reported that two larger radiotherapy sessions delivered over eight days achieved control for early-stage prostate cancer with a safety and tolerability profile...

Duravityte is advancing an implantable biologics concept designed to replace traditional manufacturing and dispensing challenges with on-body production of therapeutic proteins. The company’s...

Regulators approved two separate indications for fam-trastuzumab deruxtecan-n, extending use of the HER2-targeted antibody-drug conjugate into additional clinical settings. The label updates...

A new nanoscopy technique from The Australian National University captured previously hidden, long-lived cell-to-cell communication structures in three dimensions, according to a Nature...

Researchers reported a fluorescent RNA sensor that is now 10x more sensitive for detecting microbial water safety risks, using improved molecular recognition that better responds to...

Illumina’s Damon Hostin argued that clinical sequencing is moving toward preemptive medicine, but market access and insurance coverage hurdles remain a gating factor. In remarks focused on...

RemeGen’s telitacicept cut proteinuria substantially in a prespecified interim look from its Phase 3 TELIGAN trial in IgA nephropathy, according to results reported in NEJM. The therapy—an...

Researchers presented new data at ESTRO 2026 on a blood-based circulating tumor DNA approach for tailoring treatment in oligometastatic breast cancer. The work uses ctDNA detected in plasma as a...

A targeted stereotactic body radiotherapy strategy showed potential to extend control in early-stage breast cancer spread, according to findings presented at the ESTRO Congress 2026. The approach...

A study presented at ESTRO 2026 suggests prostate cancer radiotherapy could be delivered in only two sessions over eight days without adding side effects versus the conventional five-fraction...

FDA approval updates for fam-trastuzumab deruxtecan were reported, indicating the agency cleared two separate new indications for the antibody-drug conjugate. The update was circulated via a...

Researchers linked metabolic stress to worsening Parkinson’s disease pathology through a mitochondrial ferroptosis pathway, according to a study highlighted in the provided article. The work...

New AAV8 gene therapy vectors, HMR-001 and its codon-optimized HMR-001z, showed efficacy signals in hemophilia A research, with results described in the excerpt. The study focuses on restoring...

A study reported that naïve CD4+ T-cells can predict CAR T therapy success in large B-cell lymphoma, addressing variability in real-world outcomes. The research aims to identify immune biomarkers...

Anomaly raised $17 million for an AI-powered payer intelligence platform, according to the report. The round was led by Sound Ventures and included participation from Alumni Ventures, Link...

IKS Health acquired healthcare AI startup ARAI to build out a specialized AI stack and reduce reliance on third-party models, the excerpt reports. The deal is positioned around improving...

The FDA approved Genentech’s Tecentriq (atezolizumab) and Tecentriq Hybreza for adjuvant treatment of muscle-invasive bladder cancer (MIBC) patients who test ctDNA-positive after cystectomy using...

RemeGen’s telitacicept won a key efficacy signal in an interim analysis of a Phase 3 trial for high-risk IgA nephropathy. Presented in a NEJM report, the study found that 39 weeks of once-weekly...